Tumor immunity portrait: An AI-driven molecular predictor combining tumor microenvironment and tumor mutational burden for immune checkpoint inhibitor response prediction

被引：0
|
作者：
Shilo, Polina [1 ]
Tarasov, Artem [1 ]
Filatova, Anna [1 ]
Danilov, Konstantin [1 ]
Valiev, Ivan [1 ]
Kotlov, Nikita [1 ]
Brown, Jessica H. [1 ]
Ogloblina, Anna [1 ]
Bagaev, Alexander [1 ]
Fowler, Nathan [1 ]
机构：
[1] BostonGene Corp, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14691
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Now and Beyond of Tumor Mutational Burden as a Predictor of Response to Immune Checkpoint Inhibitors
    Nandakumar, Vijayalakshmi
    Mills, John R.
    [J]. CLINICAL CHEMISTRY, 2019, 65 (02) : 357 - 357
  • [2] INTEGRATING TUMOR MUTATIONAL BURDEN AND TRANSCRIPTOME EXPRESSION INTO PREDICTION OF IMMUNE CHECKPOINT INHIBITOR RESPONSE AND PROGNOSIS OF PATIENTS WITH COLON CANCER
    Liang, L.
    Jiang, W.
    Zheng, Y.
    Liu, T.
    Shen, X.
    Chen, Y.
    [J]. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 73 (02):
  • [3] Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
    Chatrath, Ajay
    Ratan, Aakrosh
    Dutta, Anindya
    [J]. ISCIENCE, 2021, 24 (03)
  • [4] AI-driven analysis of collagen characteristics in the tumor immune microenvironment predicts immune checkpoint inhibitors treatment responsiveness in gastric cancer
    Kim, Minji
    Redekop, Ekaterina
    Choi, Yoonho
    Lee, Sung Hak
    Cheong, Jae-Ho
    Aoki, Yu
    Shitara, Kohei
    Hwang, Tae Hyun
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [5] Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
    H. Kim
    Y. J. Heo
    Y. A. Cho
    S. Y. Kang
    S. Ahn
    K. -M. Kim
    [J]. Clinical and Translational Oncology, 2022, 24 : 556 - 567
  • [6] Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
    Kim, H.
    Heo, Y. J.
    Cho, Y. A.
    Kang, S. Y.
    Ahn, S.
    Kim, K. M.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2022, 24 (03): : 556 - 567
  • [7] Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
    Lee, Mark
    Samstein, Robert M.
    Valero, Cristina
    Chan, Timothy A.
    Morris, Luc G. T.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (01) : 112 - 115
  • [8] Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
    Nassar, Amin H.
    Adib, Elio
    Alaiwi, Sarah Abou
    El Zarif, Talal
    Groha, Stefan
    Akl, Elie W.
    Nuzzo, Pier Vitale
    Mouhieddine, Tarek H.
    Perea-Chamblee, Tomin
    Taraszka, Kodi
    El-Khoury, Habib
    Labban, Muhieddine
    Fong, Christopher
    Arora, Kanika S.
    Labaki, Chris
    Xu, Wenxin
    Sonpavde, Guru
    Haddad, Robert I.
    Mouw, Kent W.
    Giannakis, Marios
    Hodi, F. Stephen
    Zaitlen, Noah
    Schoenfeld, Adam J.
    Schultz, Nikolaus
    Berger, Michael F.
    MacConaill, Laura E.
    Ananda, Guruprasad
    Kwiatkowski, David J.
    Choueiri, Toni K.
    Schrag, Deborah
    Carrot-Zhang, Jian
    Gusev, Alexander
    [J]. CANCER CELL, 2022, 40 (10) : 1161 - +
  • [9] Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population
    Scobie, Micaela R.
    Zhou, Katherine I.
    Ahmed, Sara
    Kelley, Michael J.
    [J]. JCO PRECISION ONCOLOGY, 2023, 7
  • [10] Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors
    Smith, Katherine E. R.
    Markovic, Svetomir N.
    [J]. CLINICAL CHEMISTRY, 2024, 70 (01) : 25 - 26
12345